Pages that link to "Q44536587"

The following pages link to Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease (Q44536587):

Displaying 43 items.

• Lysophosphatidylcholine modulates fibril formation of amyloid beta peptide (Q24323259) (← links)
• Metabolomics Reveals New Mechanisms for Pathogenesis in Barth Syndrome and Introduces Novel Roles for Cardiolipin in Cellular Function (Q28390562) (← links)
• Hippocampal lipid differences in Alzheimer's disease: a human brain study using matrix-assisted laser desorption/ionization-imaging mass spectrometry (Q28391606) (← links)
• Biofluid lipidome: a source for potential diagnostic biomarkers (Q33822645) (← links)
• Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease (Q33915435) (← links)
• Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis (Q34007818) (← links)
• Choline-containing phospholipids in microdissected human Alzheimer's disease brain senile plaque versus neuropil (Q34421898) (← links)
• Aging-related Changes in Mouse Serum Glycerophospholipid Profiles (Q34800397) (← links)
• Mass Spectrometry-based Lipidomics and Its Application to Biomedical Research (Q35332947) (← links)
• Annotation of the human cerebrospinal fluid lipidome using high resolution mass spectrometry and a dedicated data processing workflow (Q35997902) (← links)
• Metabolic profiles revealed synergistically antidepressant effects of lilies and Rhizoma Anemarrhenae in a rat model of depression. (Q36232273) (← links)
• The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment (Q36428387) (← links)
• Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly (Q36473605) (← links)
• Lipids and the pathogenesis of Alzheimer's disease: is there a link? (Q36508071) (← links)
• Promotion of oxidative lipid membrane damage by amyloid beta proteins (Q36528165) (← links)
• Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers (Q36590043) (← links)
• Alzheimer's disease: the lipid connection (Q36994590) (← links)
• Chemotherapy-related changes in central nervous system phospholipids and neurocognitive function in childhood acute lymphoblastic leukemia (Q37352921) (← links)
• Plasma phospholipids identify antecedent memory impairment in older adults. (Q37714213) (← links)
• Oxidative Stress and Cell Membranes in the Pathogenesis of Alzheimer's Disease (Q37847817) (← links)
• Lipid metabolism in Alzheimer's disease (Q38204719) (← links)
• Defective lipid metabolism in neurodegeneration with brain iron accumulation (NBIA) syndromes: not only a matter of iron (Q38258626) (← links)
• Lipidomic analysis of cerebrospinal fluid by mass spectrometry-based methods (Q38285578) (← links)
• Amyloid and Tau Biomarkers in Subjective Cognitive Impairment (Q38592259) (← links)
• Lysophosphatidylcholines to phosphatidylcholines ratio predicts advanced knee osteoarthritis (Q39782431) (← links)
• Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid (Q40289797) (← links)
• Souvenaid®: a new approach to management of early Alzheimer's disease (Q43864462) (← links)
• Sleep deprivation predisposes liver to oxidative stress and phospholipid damage: a quantitative molecular imaging study (Q46790260) (← links)
• Reduced phospholipid breakdown in Alzheimer's brains: a 31P spectroscopy study (Q49068810) (← links)
• LPCAT1 controls phosphate homeostasis in a zinc-dependent manner. (Q49906630) (← links)
• Plasma lipids metabolism in mild cognitive impairment and Alzheimer's disease (Q50041775) (← links)
• Alterations in the Plasma Levels of Specific Choline Phospholipids in Alzheimer's Disease Mimic Accelerated Aging. (Q50417000) (← links)
• Using direct infusion mass spectrometry for serum metabolomics in Alzheimer's disease. (Q53356993) (← links)
• Pre-conditioning with CDP-choline attenuates oxidative stress-induced cardiac myocyte death in a hypoxia/reperfusion model. (Q55508430) (← links)
• Particular CSF sphingolipid patterns identify iNPH and AD patients (Q58751934) (← links)
• Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury (Q58758491) (← links)
• An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases (Q64057248) (← links)
• Converging and Differential Brain Phospholipid Dysregulation in the Pathogenesis of Repetitive Mild Traumatic Brain Injury and Alzheimer's Disease (Q64229388) (← links)
• A comprehensive metabolomics investigation of hippocampus, serum, and feces affected by chronic fluoxetine treatment using the chronic unpredictable mild stress mouse model of depression (Q64268437) (← links)
• Porcine liver decomposition product-derived lysophospholipids promote microglial activation in vitro (Q89948172) (← links)
• Perspective: The Potential Role of Circulating Lysophosphatidylcholine in Neuroprotection against Alzheimer Disease (Q90452789) (← links)
• Cerebrospinal fluid lipidomics: effects of an intravenous triglyceride infusion and apoE status (Q91942413) (← links)
• Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers (Q92423135) (← links)